scholarly journals Methylation of CDX2 gene promoter in the prediction of treatment efficacy in colorectal cancer

2018 ◽  
Author(s):  
Yunshuai Wang ◽  
Zhaohui Li ◽  
Wenxian Li ◽  
Shuaifeng Liu ◽  
Baowei Han
Keyword(s):  
Colorectal Cancer ◽  
Treatment Efficacy ◽  
Gene Promoter ◽  
Prediction Of Treatment Efficacy

scholarly journals Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zijian Chen ◽  
Zenghong Huang ◽  
Yanxin Luo ◽  
Qi Zou ◽  
Liangliang Bai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Promoter Methylation ◽  
Expression Profiles ◽  
Methylation Status ◽  
Gene Promoter ◽  
Normal Mucosa ◽  
Suppressor Gene ◽  
Survival Outcome ◽  
Prognostic Models

Abstract Background Neurotrophic tropomyosin receptor kinases (NTRKs) are a gene family function as oncogene or tumor suppressor gene in distinct cancers. We aimed to investigate the methylation and expression profiles and prognostic value of NTRKs gene in colorectal cancer (CRC). Methods An analysis of DNA methylation and expression profiles in CRC patients was performed to explore the critical methylations within NTRKs genes. The methylation marker was validated in a retrospectively collected cohort of 229 CRC patients and tested in other tumor types from TCGA. DNA methylation status was determined by quantitative methylation-specific PCR (QMSP). Results The profiles in six CRC cohorts showed that NTRKs gene promoter was more frequently methylated in CRC compared to normal mucosa, which was associated with suppressed gene expression. We identified a specific methylated region within NTRK3 promoter targeted by cg27034819 and cg11525479 that best predicted survival outcome in CRC. NTRK3 promoter methylation showed independently predictive value for survival outcome in the validation cohort (P = 0.004, HR 2.688, 95% CI [1.355, 5.333]). Based on this, a nomogram predicting survival outcome was developed with a C-index of 0.705. Furthermore, the addition of NTRK3 promoter methylation improved the performance of currently-used prognostic model (AIC: 516.49 vs 513.91; LR: 39.06 vs 43.64, P = 0.032). Finally, NTRK3 promoter methylation also predicted survival in other tumors, including pancreatic cancer, glioblastoma and stomach adenocarcinoma. Conclusions This study highlights the essential value of NTRK3 methylation in prognostic evaluation and the potential to improve current prognostic models in CRC and other tumors.

E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer

2011 ◽  
Vol 27 (2) ◽  
pp. 151-158 ◽  
Author(s):  
Yadong Wang ◽  
Haiyan Yang ◽  
Li Li ◽  
Haiyu Wang ◽  
Congke Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gene Promoter ◽  
Promoter Polymorphism ◽  
Cdh1 Gene ◽  
Gene Promoter Polymorphism ◽  
E Cadherin

scholarly journals Bevacizumab Beyond Progression: How to Monitor Treatment Efficacy? Results of a Functional Imaging Study in Murine Colorectal Cancer

2012 ◽  
Vol 23 ◽  
pp. ix192
Author(s):  
L. Heijmen ◽  
E.E.G.W. Te Voert ◽  
C.J.A. Punt ◽  
L. De Geus-Oei ◽  
A. Heerschap ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Functional Imaging ◽  
Treatment Efficacy ◽  
Imaging Study ◽  
Functional Imaging Study

200 Aberrant Gene Promoter Methylation Is Associated with Colorectal Cancer Multiplicity

2009 ◽  
Vol 136 (5) ◽  
pp. A-37
Author(s):  
Victoria Gonzalo ◽  
Juan José Lozano ◽  
Jenifer Muñoz ◽  
Francesc Balaguer ◽  
Maria Dolores Giraldez ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Promoter Methylation ◽  
Gene Promoter ◽  
Aberrant Gene

A/G Polymorphism of the MMP-7 Gene Promoter Region in Colorectal Cancer

2011 ◽  
Vol 83 (11) ◽  
Author(s):  
Łukasz Dziki ◽  
Karolina Przybyłowska ◽  
Ireneusz Majsterek ◽  
Radzisław Trzciński ◽  
Michał Mik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Promoter Region ◽  
Gene Promoter ◽  
Gene Promoter Region
Sign in / Sign up

Export Citation Format

Share Document